Judge Rejects Merck's Challenge to Inflation Reduction Act Drug Price Program

A federal judge in Washington D.C. has ruled against Merck in its lawsuit challenging the Inflation Reduction Act's Drug Price Negotiation Program. The program allows the Department of Health and Human Services (HHS) to negotiate prices for certain Medicare-covered drugs, which has raised concerns among pharmaceutical companies like Merck.

The judge rejected Merck's claim that its participation in the program was voluntary, stating that the company had already agreed to participate in negotiations. This ruling means that Merck will be subject to price controls as part of the program.